152 related articles for article (PubMed ID: 11926629)
1. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Di PR; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2002 Mar; 88(3):331-4. PubMed ID: 11926629
[TBL] [Abstract][Full Text] [Related]
2. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
Quiralte J; Sáenz de San Pedro B; Florido JJ
Ann Allergy Asthma Immunol; 2002 Jul; 89(1):63-6. PubMed ID: 12141722
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
4. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
Perrone MR; Artesani MC; Viola M; Gaeta F; Caringi M; Quaratino D; Romano A
Int Arch Allergy Immunol; 2003 Sep; 132(1):82-6. PubMed ID: 14555862
[TBL] [Abstract][Full Text] [Related]
6. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs.
Pacor ML; Di Lorenzo G; Biasi D; Barbagallo M; Corrocher R
Clin Exp Allergy; 2002 Mar; 32(3):397-400. PubMed ID: 11940070
[TBL] [Abstract][Full Text] [Related]
7. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
[TBL] [Abstract][Full Text] [Related]
8. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
[TBL] [Abstract][Full Text] [Related]
9. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
10. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
[TBL] [Abstract][Full Text] [Related]
11. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs.
Quaratino D; Romano A; Di Fonso M; Papa G; Perrone MR; D'Ambrosio FP; Venuti A
Ann Allergy Asthma Immunol; 2000 Jun; 84(6):613-7. PubMed ID: 10875490
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Bavbek S; Celik G; Pasaoglu G; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
[TBL] [Abstract][Full Text] [Related]
14. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Quiralte J; Delgado J; Sáenz de San Pedro B; López-Pascual E; Nieto MA; Ortega N; Florido JF; Conde J
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.
Asero R
Ann Allergy Asthma Immunol; 1999 Jun; 82(6):554-8. PubMed ID: 10400483
[TBL] [Abstract][Full Text] [Related]
16. Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria.
Nettis E; Di Paola R; Napoli G; Ferrannini A; Tursi A
Allergy; 2002 May; 57(5):442-5. PubMed ID: 11972485
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
18. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
[TBL] [Abstract][Full Text] [Related]
19. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Sánchez-Borges M; Capriles-Hulett A; Caballero-Fonseca F
Am J Clin Dermatol; 2002; 3(9):599-607. PubMed ID: 12444802
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
